Storm Therapeutics Raises $56M Series C to Advance RNA Cancer Therapy…

Team S · 2026-04-17T14:15:44.000Z

UK-based biotech startup Storm Therapeutics has closed a $56 million Series C funding round to accelerate the clinical development of its lead oncology program, reinforcing investor confidence in next-generation RNA-targeting cancer therapies. The newly raised capital will primarily be used to advance STC-15 through Phase II clinical trials across multiple indications, with the company aiming to generate data that could support accelerated regulatory approval pathways. Storm Therapeutics is focused on targeting RNA-modifying enzymes involved in disease progression. Its lead candidate, STC-15, inhibits METTL3, an enzyme responsible for messenger RNA methylation—a process increasingly recognized as a key driver in tumor growth and cancer cell survival. The upcoming Phase II studies will evaluate STC-15 in selected sarcoma indications. Sarcomas are rare but aggressive cancers affecting bone, muscle, fat, cartilage, blood vessels, and connective tissues. These tumors often respond poorly to conventional targeted therapies or immunotherapies, creating significant unmet medical need. According to available early-stage clinical data, STC-15 demonstrated durable tumor regression across multiple sarcoma subtypes in Phase I testing, increasing optimism around its differentiated mechanism of action. By disrupting METTL3-driven biology, the therapy aims to induce cell-cycle arrest and apoptosis in malignant cells. Storm Therapeutics has emerged as one of Europe’s more closely watched precision oncology biotech companies, positioning itself within the rapidly expanding field of epitranscriptomics an area exploring how RNA modifications can be harnessed for therapeutic innovation. With fresh capital secured, the company is now focused on translating promising science into late-stage clinical progress, potentially opening a new treatment avenue for patients with difficult-to-treat cancers.

Member Login Get Access

Storm Therapeutics Raises $56M Series C to Advance RNA Cancer Therapy… | Newnex